Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer

A compound of Formula II:

• or a pharmaceutically acceptable salt thereof, wherein
• CyN is a cyclic amine group bound via a nitrogen atom that is optionally substituted with one or more substituents independently chosen from halogen, C1-C2alkyl, and C1-C2alkoxy;
• X is C or N;
• R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino;
• m and n are each independently 1, 2, or 3;
• and
• represents either a single bond or a double bond,
• wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.